New Agents for Treatment of Lymphomas: Which Ones Will Succeed?
F B Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. March 2008

Xcytrin® (Motexafin Gadolinium) May Improve Results of Zevalin® for Treatment of Refractory NHL (10/26/2009)
Researchers from the Robert H Lurie Comprehensive Cancer Center have reported that the addition of Xcytrin® to Zevalin® ([90Y] ibritumomab tiuxetan) may improve treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The details of this study appeared early online in Clinical Cancer Research.

Torisel® Active in Relapsed or Refractory Mantle Cell Lymphoma (10/21/2009)
Researchers from Germany have reported that Torisel® (temsirolimus) improves progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL). The details of this Phase III study were published in the August, 2009 issue of the Journal of Clinical Oncology.

Cytarabine Improves Results of High-dose Methotrexate in Patients with Primary CNS Lymphoma (10/9/2009)
Researchers involved in a multicenter European-South American study have reported that the addition of high-dose cytarabine to high-dose methotrexate improves the response rate in patients with primary central nervous system lymphoma (PCNSL). The details of this study were published early online on September 20, 2009 in The Lancet.

Twenty-year Results Reported of Autologous Stem Cell Transplants for Hodgkin’s Lymphoma (10/7/2009)
Researchers from the Memorial Sloan-Kettering Cancer Center have reported that accelerated involved field fractionated radiotherapy (IFRT) followed by total lymphoid irradiation (TLI) prior to autologous stem cell transplantation (ASCT) is effected therapy for previously unirradiated patients with refractory or relapsed Hodgkin’s lymphoma (HL). The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

Zevalin® Active for Treatment of Extranodal Marginal-zone Lymphoma (10/6/2009)
Researchers from Italy have reported that patients with relapsed or refractory extranodal marginal-zone lymphoma have a high response rate following treatment with Zevalin® (90Yttrium-ibritumomab tiuxetan). The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.